However, trials testing the efficacy of FGFR inhibitors in patients with F3T3 gliomas have demonstrated only moderate efficacy in comparison to the remarkable results obtained in other cancers harboring the FGFR3::TACC3 fusion [13]. The gene discussed is TACC3; the disease is central nervous system cancer.